Serial transcriptome analysis and cross-species integration identifies centromere-associated protein e as a novel neuroblastoma target

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2749-2758

  Balamuth, Naomi J ^a   Wood, Andrew ^a   Wang, Qun ^a   Jagannathan, Jayanti ^a   Mayes, Patrick ^a   Zhang, Zhe ^b   Chen, Zhongxue ^b   Rappaport, Eric ^b   Courtright, Joshua ^a   Pawel, Bruce ^a   Weber, Barbara ^d   Wooster, Richard ^d   Sekyere, Eric O ^e   Marshall, Glenn M ^e   Maris, John M ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d GLAXOSMITHKLINE   (United States)

^e SYDNEY CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE PROTEIN E; G PROTEIN COUPLED RECEPTOR; INOSINATE DEHYDROGENASE; PROTEIN GPR49; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RNA ANALYSIS; TUMOR GROWTH;

ALGORITHMS; ANIMALS; CELL GROWTH PROCESSES; CHROMOSOMAL PROTEINS, NON-HISTONE; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIES SPECIFICITY; TRANSCRIPTIONAL ACTIVATION;

EID: 77950828308     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3844     Document Type: Article

References (35)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-2120
2. Matthay KK, Villablanca JG, Seeger RC, et al, Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173
3. 3. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005;6: 649-658 (Pubitemid 41222755)
4. 4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582 (Pubitemid 44547808)
5. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008;51:679-683
6. Yu AL, Gilman AL, Ozkaynak MF, et al. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032 [abstract 10067z]. J Clin Oncol 2009;27.
7. 7. Mosse YP, Diskin SJ, Wasserman N, et al. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 2007;46:936-949 (Pubitemid 47435023)
8. 8. Spitz R, Oberthuer A, Zapatka M, et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer 2006;45:1130-1142 (Pubitemid 44763441)
9. Vandesompele J, Baudis M, De Preter K, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23: 2280-2299
10. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-1033
11. 11. Brodeur G, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-1124 (Pubitemid 14106392)
12. 12. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116 (Pubitemid 16216827)
13. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet 2009; 41:718-723
14. Maris JM, Mosse YP, Bradfield JP, et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008;358:2585-2593
15. Diskin SJ, Hou C, Glessner JT, et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 2009;459:987-991
16. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935
17. 17. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-2995 (Pubitemid 27234938)
18. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci U S A 2004;101:12664-12669
19. 19. Chesler L, Goldenberg DD, Seales IT, et al. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 2007;67:9435-9442 (Pubitemid 47541995)
20. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-6062
21. 21. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129-2141 (Pubitemid 37161770)
22. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008.
23. Zeller Kl, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003;4:R69.
24. Cole KA, Attiyeh EF, Mosse YP, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008;6:735-742
25. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6:99-106.
26. Van Roy N, De Preter K, Hoebeeck J, et al. The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Med 2009;1:74.
27. Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-5273
28. 28. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by cross-species geneexpression analysis. Nat Genet 2005;37:48-55. (Pubitemid 40070939)
29. Louis SF, Vermolen BJ, Garini Y, et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci U S A 2005;102:9613-9618
30. 30. Yamamoto Y, Sakamoto M, Fujii G, et al. Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with β-catenin mutations. Hepatology 2003;37:528-533 (Pubitemid 36258773)
31. Tanese K, Fukuma M, Yamada T, et al. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol 2008;173:835-843
32. McClanahan T, Koseoglu S, Smith K, et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther 2006;5:419-426
33. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007;8:379-393
34. Wood KW, Chua P, Sutton D, Jackson JR. Centromere-associated protein E: a motor that puts the brakes on the mitotic checkpoint. Clin Cancer Res 2008;14:7588-7592
35. Hu ZKW, Das D, Ziyad S, et al. Small molecular inhibitory of the centromere-associated protein E (CENP-E), GSK923295A inhibits cell growth in breast cancer cells. AACR: Denver (CO); 2009.